Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size

Ewing Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (11 / 26 / 2012)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview

Recommended Related to Cancer

Treatment for Extramedullary Plasmacytoma

Standard Treatment Options for Extramedullary Plasmacytoma Standard treatment options for extramedullary plasmacytoma include the following: Radiation therapy to the isolated lesion with fields that cover the regional lymph nodes, if possible.[1,2] In some cases, surgical resection may be considered, but it is usually followed by radiation therapy.[2] If the monoclonal (or myeloma) protein (M protein) persists or reappears, the patient may need further radiation therapy. In...

Read the Treatment for Extramedullary Plasmacytoma article > >

Added text to state that the duration of primary chemotherapy ranges from 6 months to approximately 1 year. Also added text to state that a randomized clinical trial from the Children's Oncology Group showed that for patients presenting without metastases, the administration of cycles of cyclophosphamide, doxorubicin, and vincristine alternating with cycles of ifosfamide and etoposide at 2-week intervals achieved superior event-free survival (EFS) than alternating cycles at 3-week intervals (cited Womer et al. as reference 20).

Added text to state that the cumulative incidence of subsequent neoplasms in children treated for Ewing sarcoma between 1970 and 1986 at 25 years after diagnosis was 9.0%. Most of these patients received radiation therapy; comparable long-term data do not yet exist for significant numbers of patients who did not receive radiation therapy (cited Ginsberg et al. as reference 65).

Ewing Sarcoma: Localized Tumors

Revised text to state that patients randomly assigned to the every 2-week interval of treatment had an improved 5-year EFS (73% vs. 65%, P = .048) (cited Womer et al. as reference 14).

Ewing Sarcoma: Recurrent Tumors

Added Malempati et al. as reference 18.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

1

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Colorectal cancer cells
A common one in both men and women.
Lung cancer xray
See it in pictures, plus read the facts.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article